Home
Scholarly Works
Phase I/II study of GTI-2040 plus docetaxel as...
Conference

Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors.

Authors

Leighl NB; Laurie SA; Knox JJ; Ellis PM; Shepherd FA; Burkes RL; Vincent M; Pond GR; Zwiebel JA; Moore MJ

Volume

23

Pagination

pp. 683S-683S

Publisher

AMER SOC CLINICAL ONCOLOGY

Publication Date

June 1, 2005

Name of conference

41st Annual Meeting of the American-Society-of-Clinical-Oncology

Conference place

Orlando, FL

Conference start date

May 13, 2005

Conference end date

May 17, 2005

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

16

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team